Mucosal Human Immunodeficiency Virus Vaccine Late Pre-clinical Evaluation
Funder
National Health and Medical Research Council
Funding Amount
$575,315.00
Summary
Despite many candidate vaccines entering clinical development for protection against HIV, none has yet been successful. This proposal centres on late preclinical development for a novel mucosal vaccine strategy for HIV, which combines a preclinically-proven approach to generating strong T cell immune responses, with an existing approach to generating broadly neutralising antibody responses to HIV. Proof of synergy between these approaches will lead directly to clinical development.
A Novel Strategy To Enhance T Cell-mediated Immunity To Vaccine Antigens
Funder
National Health and Medical Research Council
Funding Amount
$234,592.00
Summary
Globally there are about 33 million people living with HIV. The disease has already resulted in 23 million deaths and 2.5 million people are newly infected each year. Similarly, TB kills nearly 2 million people every year and infects about 1% of the worldÍs population every year. A vaccine is the best and also likely the only long-term solution for HIV/TB disease prevention. This research proposal looks at novel strategies to increase the efficacy of vaccines for diseases such as HIV/TB.
Development Of Stable Human Antibody Phage Display Libraries
Funder
National Health and Medical Research Council
Funding Amount
$539,644.00
Summary
Antibodies are blockbuster therapeutics for the treatment of cancer and inflammation. Unfortunately, they often display limited stability which greatly hinders development and production. This project focuses on the construction of large libraries of stable antibodies, thereby streamlining the development of new therapeutics.
Cancer Immunotherapy Utilizing A Novel Receptor For Programmed Cell Death-1 Ligand 2
Funder
National Health and Medical Research Council
Funding Amount
$577,857.00
Summary
Immuno-modulators utilize the patient’s own immune system to eliminate or slow the growth of cancerous cells. We have identified a novel immuno-modulator which could be a significant player in immune-modulation therapy for the treatment of cancer. We will use the development grant to develop a product which has significant potential to be the next generation treatment for cancer.
Pre-clinica Evaluation Of A Novel HIV-1 Vaccine Statrgy
Funder
National Health and Medical Research Council
Funding Amount
$528,440.00
Summary
Recently, we have designed two mucosal HIV vaccine strategies that temporary block hormone-like molecules IL-4/IL-13 at the vaccination site inducing excellent antibody and killer T cell immunity with protective efficacy in small animals. This project aims to evaluate the safety and efficacy of these novel HIV mucosal vaccines prior to clinical evaluation.